A manufacturer of over-the-counter (OTC) drugs faced executive compensation, equity compensation and employee benefit issues arising in connection with its acquisition of an Irish corporation in a corporate inversion cash and stock deal valued at approximately $8.6 billion. Our firm represented the manufacturer.
Manufacturer Faces Issues Arising From Acquisition
Lead Contacts
